Literature DB >> 3875366

Interferon is effective in hairy-cell leukaemia.

C P Worman, D Catovsky, P C Bevan, L Camba, M Joyner, P J Green, H J Williams, J M Bottomley, E C Gordon-Smith, J C Cawley.   

Abstract

Seventeen patients with hairy-cell leukaemia (HCL) and peripheral cytopenias were given human lymphoblastoid interferon (Wellferon), 3 megaunits daily or 6 megaunits on alternate days intramuscularly, for 4-24 weeks. Twelve of the patients had undergone splenectomy, three had no palpable spleen and had therefore not been offered surgery, and two patients with substantial splenomegaly were given interferon (IFN) as treatment of first choice. Toxic effects were minor except in one patient who experienced a severe form of somnolence syndrome. In all patients hairy cells (HCs) were cleared from the blood and platelet and Hb levels improved in 2-14 weeks. Neutrophils were improved in 14/17 of the patients. In the two patients with splenomegaly, the spleen became impalpable after 5-8 weeks therapy, and haematological improvement occurred at 12-14 weeks. HC infiltration of the marrow was reduced in all patients, but was complete (less than 5%) in only two, both of whom had impalpable spleens. Immunological surface-marker studies confirmed that light-chain-restricted B cells disappeared from the blood in parallel with the clearance of morphological HCs. There was no evidence of HC maturation and no increase in phenotypic NK cells. T cells were moderately reduced and the relatively greater reduction of Leu 2a+ suppressor cells resulted in increased Leu 3a+/2a+ helper/suppressor ratios in 11/17 of the patients. Early experience in the six patients who have stopped IFN suggests that, after an initial further increase in Hb and neutrophil levels, HCs gradually return with slow deterioration of haematological parameters. Interferon is now the treatment of choice for patients becoming cytopenic post-splenectomy or for patients without splenomegaly. IFN is effective first-line therapy in patients with splenomegaly, but further work is needed to establish whether the agent should replace splenectomy in such patients. Some form of maintenance or re-treatment therapy will probably be necessary.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3875366     DOI: 10.1111/j.1365-2141.1985.tb07480.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  16 in total

1.  Reticulin fibre content of bone marrow infiltrates of malignant non-Hodgkin's lymphomas (B-cell type, low malignancy)--a morphometric evaluation before and after therapy.

Authors:  J Thiele; J Langohr; M Skorupka; R Fischer
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1990

2.  Treatment of early stage-B chronic lymphocytic leukemia with alpha-2b interferon after chlorambucil reduction of the tumoral mass.

Authors:  E Montserrat; N Villamor; A Urbano-Ispizua; J M Ribera; M Lozano; J L Vives-Corrons; C Rozman
Journal:  Ann Hematol       Date:  1991-07       Impact factor: 3.673

3.  The effect of interferons on cellular differentiation.

Authors:  T Moritz; H Kirchner
Journal:  Blut       Date:  1986-11

4.  Hairy cell leukemia: 1986.

Authors:  D Catovsky
Journal:  Br Med J (Clin Res Ed)       Date:  1986-03-22

5.  [Therapeutic procedure in hairy cell leukemia].

Authors:  P von Wussow
Journal:  Klin Wochenschr       Date:  1987-07-15

Review 6.  Hairy cell leukemia: clinical features and therapeutic advances.

Authors:  B C Lembersky; H M Golomb
Journal:  Cancer Metastasis Rev       Date:  1987       Impact factor: 9.264

Review 7.  Interferon for treatment: the dust settles.

Authors:  D Galvani; S D Griffiths; J C Cawley
Journal:  Br Med J (Clin Res Ed)       Date:  1988-06-04

8.  Primary treatment of hairy cell leukemia: should IFN-therapy replace splenectomy?

Authors:  F Porzsolt
Journal:  Blut       Date:  1986-05

9.  [Beta interferon therapy in hairy cell leukemia].

Authors:  P von Wussow; J Dühlmann; T Grethlein; W D Hirschmann; E Hügl; O Koch; W R Martin; H W Pees; W Urbanitz; M Freund
Journal:  Klin Wochenschr       Date:  1987-07-15

10.  Natural IFN-alpha therapy in hairy-cell leukaemia (namalva-type IFN--Wellferon).

Authors:  C P Worman; A B Nethersell; J M Bottomley; K Apostolov; W Barker; J C Cawley
Journal:  Klin Wochenschr       Date:  1987-07-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.